Camila F Rizzi1, Marcos B Ferraz2, Dalva Poyares1, Sergio Tufik1. 1. Sleep Medicine and Biology Discipline, Psychobiology Department, Universidade Federal de Sao Paulo, Sao Paulo, Brazil. 2. Sleep Medicine and Biology Discipline, Psychobiology Department, Universidade Federal de Sao Paulo, Sao Paulo, Brazil: Sao Paulo Center for Health Economics - GRIDES, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
Abstract
STUDY OBJECTIVES: To estimate the health utility score and quality-adjusted life-years (QALY) index of obstructive sleep apnea syndrome (OSAS) in patients over 1 y of continuous positive airway pressure (CPAP) treatment. DESIGN: Longitudinal interventional study. SETTING: The study was carried out in Sao Paulo Sleep Institute, Brazil. PATIENTS AND PARTICIPANTS: Ninety-five patients with OSAS and with apnea-hypopnea index (AHI) > 20 of either sex, body mass index < 40 kg/m(2), and no previous contact with CPAP were included. INTERVENTIONS: The participants underwent baseline and titration polysomnographies, clinical evaluation, and ambulatory blood pressure (BP) measurement, completed Short-Form 6 Dimension Health Survey (SF-6D) and Epworth Sleepiness Scale (ESS) questionnaires, and implementation of CPAP. The patients were followed for 1 y. MEASUREMENTS AND RESULTS: The mean AHI and age were 57.6 ± 29.2 events/h and 53.3 ± 9.3 y, respectively. One year of CPAP treatment increased the health utility score from 0.611 ± 0.112 to 0.710 ± 0.121 (P < 0.01). Therefore, CPAP resulted in a mean gain of 0.092 QALY/patient. The improvements in utility scores were associated with decreases in the ESS after 1 mo, in systolic BP after 1 y, and in diastolic BP at 6 mo. BP normalization group (≤ 130/85 mmHg) showed higher QALY than that of the non-normalization group (0.10 ± 0.09 versus 0.05 ± 0.10; P = 0.03). One-year ESS score (P = 0.03), diastolic BP reduction P = 0.01) and baseline utility scores (P < 0.01) were significantly associated with QALY gain. CONCLUSION: This study showed a significant QALY/patient gain after 1 y of regular CPAP use. In addition, BP normalization was associated with higher QALY gain. Thus, utility studies can provide more complete analyses of the total benefits of CPAP treatment in patients with OSAS and should be encouraged.
STUDY OBJECTIVES: To estimate the health utility score and quality-adjusted life-years (QALY) index of obstructive sleep apnea syndrome (OSAS) in patients over 1 y of continuous positive airway pressure (CPAP) treatment. DESIGN: Longitudinal interventional study. SETTING: The study was carried out in Sao Paulo Sleep Institute, Brazil. PATIENTS AND PARTICIPANTS: Ninety-five patients with OSAS and with apnea-hypopnea index (AHI) > 20 of either sex, body mass index < 40 kg/m(2), and no previous contact with CPAP were included. INTERVENTIONS: The participants underwent baseline and titration polysomnographies, clinical evaluation, and ambulatory blood pressure (BP) measurement, completed Short-Form 6 Dimension Health Survey (SF-6D) and Epworth Sleepiness Scale (ESS) questionnaires, and implementation of CPAP. The patients were followed for 1 y. MEASUREMENTS AND RESULTS: The mean AHI and age were 57.6 ± 29.2 events/h and 53.3 ± 9.3 y, respectively. One year of CPAP treatment increased the health utility score from 0.611 ± 0.112 to 0.710 ± 0.121 (P < 0.01). Therefore, CPAP resulted in a mean gain of 0.092 QALY/patient. The improvements in utility scores were associated with decreases in the ESS after 1 mo, in systolic BP after 1 y, and in diastolic BP at 6 mo. BP normalization group (≤ 130/85 mmHg) showed higher QALY than that of the non-normalization group (0.10 ± 0.09 versus 0.05 ± 0.10; P = 0.03). One-year ESS score (P = 0.03), diastolic BP reduction P = 0.01) and baseline utility scores (P < 0.01) were significantly associated with QALY gain. CONCLUSION: This study showed a significant QALY/patient gain after 1 y of regular CPAP use. In addition, BP normalization was associated with higher QALY gain. Thus, utility studies can provide more complete analyses of the total benefits of CPAP treatment in patients with OSAS and should be encouraged.
Authors: Mark S Aloia; J Todd Arnedt; Leisha Smith; Jaime Skrekas; Michael Stanchina; Richard P Millman Journal: Sleep Med Date: 2005-01-24 Impact factor: 3.492
Authors: Mohammed Albarrak; Katsuhisa Banno; Ahmed Al Sabbagh; Kenneth Delaive; Randy Walld; Jure Manfreda; Meir H Kryger Journal: Sleep Date: 2005-10 Impact factor: 5.849
Authors: Clete A Kushida; Michael R Littner; Timothy Morgenthaler; Cathy A Alessi; Dennis Bailey; Jack Coleman; Leah Friedman; Max Hirshkowitz; Sheldon Kapen; Milton Kramer; Teofilo Lee-Chiong; Daniel L Loube; Judith Owens; Jeffrey P Pancer; Merrill Wise Journal: Sleep Date: 2005-04 Impact factor: 5.849
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Alex Sassani; Larry J Findley; Meir Kryger; Eric Goldlust; Charles George; Terence M Davidson Journal: Sleep Date: 2004-05-01 Impact factor: 5.849
Authors: Lauren J Luk; Toby O Steele; Jess C Mace; Zachary M Soler; Luke Rudmik; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2015-07-03 Impact factor: 3.858
Authors: Toby O Steele; Jess C Mace; Raj Dedhia; Luke Rudmik; Timothy L Smith; Jeremiah A Alt Journal: Int Forum Allergy Rhinol Date: 2016-06-16 Impact factor: 3.858
Authors: Tetyana Kendzerska; Tara Gomes; Atul Malhotra; Andrea S Gershon; Marcus Povitz; Daniel I McIsaac; Shawn D Aaron; Frances Chung; Gregory L Bryson; Robert Talarico; Tahmid Ahmed; Michael Godbout; Peter Tanuseputro Journal: PLoS One Date: 2022-06-28 Impact factor: 3.752
Authors: Fabienne L Huber; Michael Furian; Malcolm Kohler; Tsogyal D Latshang; Yvonne Nussbaumer-Ochsner; Alexander Turk; Otto D Schoch; Irene Laube; Robert Thurnheer; Konrad E Bloch Journal: Respiration Date: 2021-02-04 Impact factor: 3.580